GeneBio Systems
Recombinant Rat MMP-2/CLG4A protein (His tag)
Recombinant Rat MMP-2/CLG4A protein (His tag)
SKU:PDER100210
Couldn't load pickup availability
Size:100μg
Storage:Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.
Shipping:This product is provided as lyophilized powder which is shipped with ice packs.
Exp date:12 months
Category ID_II:Recombinant Proteins
Category ID_III:Others
Abbreviation:MMP-2;CLG4A
Target Synonym:72 kDa Gelatinase;72 kDa Type IV Collagenase;CLG4;CLG4A;Gelatinase A;MMP-2;MMP-II;MMP2;MONA;Matrix Metalloproteinase-2;TBE-1
Research Areas:Cell biology;Cardiovascular;Cancer;metabolism
Conjugation:
Target Species:Rat
Expression Host:E.coli
Application:
Fusion tag:N-His
UNIProt ID:P33436
Accession:P33436
Background:Matrix Metalloproteinase-2 (MMP-2) is an enzyme that degrades components of the extracellular matrix and thus plays a pivotal role in cell migration during physiological and pathological processes. MMP-2 expression is dependent on extracellular matrix metalloproteinase inducer (EMMPRIN), Her2/neu, growth factors, cytokines, and hormones. Pro-MMP-2 activation needs MT1-MMP and TIMP-2 contribution. MMP-2 is changed in distribution and increased in amount in the ventral cochlear nucleus after unilateral cochlear ablation. A low level of MMP-2 is linked to favorable prognosis in patients with a hormone receptor-negative tumor, usually associated with high risk. As a zymogen requiring proteolytic activation for catalytic activity, MMP-2 has been implicated broadly in the invasion and metastasis of many cancer model systems, including human breast cancer (HBC). Blocking MMP-2 secretion and activation during breast carcinoma development may decrease metastasis. The detection of active MMP-2 alone or the rate of pro-MMP-2 and active MMP-2 is considered a very sensitive indicator of cancer metastasis. Modulation of MMP-2 expression and activation through specific inhibitors and activators may thus provide a new mechanism for breast cancer treatment.
Concentration:
Activity:Not validated for activity
Sequence:Tyr 395-Cys 662
Purity: > 95% as determined by reducing SDS-PAGE.
Formulation:Lyophilized from sterile PBS, pH 7.4.
Normally 5%-8% trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the printed manual.
Reconstitution:It is recommended that sterile water be added to the vial to prepare a stock solution of 0.5 mg/mL. Concentration is measured by UV-Vis.
Endotoxin:< 10 EU/mg of the protein as determined by the LAL method.
Calculated MW:29.4 kDa
ObservedMW:35 kDa
